<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31454201</article-id><article-id pub-id-type="pmc">6713370</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Could Cerebrospinal Fluid Biomarkers Offer Better Predictive Value
for Spinal Cord Ischaemia Than Current Neuromonitoring Techniques During
Thoracoabdominal Aortic Aneurysm Repair - A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Harky</surname><given-names>Amer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MRCS, MSc</role></contrib><contrib contrib-type="author"><name><surname>Fok</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MRCS</role></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>Holly</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MBBS</role></contrib><contrib contrib-type="author"><name><surname>Howard</surname><given-names>Callum</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rimmer</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MBBS</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9095-6994</contrib-id><name><surname>Bashir</surname><given-names>Mohamad</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiothoracic Surgery, Liverpool Heart and Chest
Hospital, Liverpool, UK.</aff><aff id="aff2">
<label>2</label> Department of Vascular Surgery, Royal Liverpool Hospital,
Liverpool, UK.</aff><aff id="aff3">
<label>3</label> School of Medicine, University of Liverpool, Liverpool, UK.</aff><aff id="aff4">
<label>4</label> Faculty of Biology, Medicine and Health, University of Manchester,
Manchester, UK.</aff><aff id="aff5">
<label>5</label> Department of Aortovascular Surgery, Manchester Royal Infirmary,
Manchester, UK.</aff><author-notes><corresp id="c1">Correspondence Address: Mohamad Bashir,
https://orcid.org/0000-0001-9095-6994, Department of Aortovascular Surgery -
Manchester Royal infirmary - Manchester, UK, Zip code: M13 9WL. E-mail:
<email>drmbashir@mail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2019</year></pub-date><volume>34</volume><issue>4</issue><fpage>464</fpage><lpage>471</lpage><history><date date-type="received"><day>19</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Cerebrospinal fluid (CSF) drainage is a technique that has significantly
reduced the incidence of spinal cord ischaemia (SCI). We present results of
a systematic review to assess the literature on this topic in relation to
thoracoabdominal aortic aneurysm repair (TAAR).</p></sec><sec><title>Methods</title><p>Major medical databases were searched to identify papers related to CSF
biomarkers measured during TAAAR.</p></sec><sec><title>Results</title><p>Fifteen papers reported measurements of CSF biomarkers with 265 patients in
total. CSF biomarkers measured included S-100&#x000df;, neuron-specific
endolase (NSE), lactate, glial fibrillary acidic protein A (GFPa), Tau, heat
shock protein 70 and 27 (HSP70, HSP27), and proinflammatory cytokines.
Lactate and S-100&#x000df; were reported the most, but did not correlate with
SCI, which was also the case with NSE and TAU. GFPa showed significant CSF
level rises, both intra and postoperative in patients who suffered SCI and
warrants further investigation, similar results were seen with HSP70, HSP27
and IL-8.</p></sec><sec><title>Conclusions</title><p>Although there is significant interest in this topic, there still remains a
significant lack of high-quality studies investigating CSF biomarkers during
TAAR to detect SCI. A large and multicentre study is required to identify
the significant role of each biomarker.</p></sec></abstract><kwd-group><kwd>Spinal Cord Ischemia</kwd><kwd>Thoracic Aortic Aneurysm</kwd><kwd>Lactic Acid</kwd><kwd>Cytokines</kwd><kwd>Biomarkers</kwd></kwd-group></article-meta></front><body><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CSF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cerebrospinal fluid</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MeSH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Medical subject
headings</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DTAAR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Descending thoracic
aortic aneurysm repair</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NSE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Neuron-specific
endolase</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">GFPa</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Glial fibrillary acidic
protein A</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= <italic>Odds
ratio</italic></td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HSP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heat shock protein</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Spinal cord
ischaemia</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IONM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intraoperative
neurophysiological monitoring</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SSEP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Somatosensory evoked
potentials</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Lactate
dehydrogenase</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAAR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Thoracoabdominal aortic
aneurysm repair</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MEPs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Motor evoked
potentials</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Tumor necrosis
fator-alpha</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Spinal cord ischaemia (SCI) is a major complication post open thoracoabdominal aortic
aneurysm repair (TAAR). The presence of TAAR is a major risk factor for sudden
death, it carries a mortality rate of 90% at 5 years if remained
unoperated<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Surgical repair can offer a good prognosis compared
to conservative management, however, such type of surgery is associated with serious
morbidities perioperatively and mortality<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>One of the major perioperative complications is the development of paraplegia, which
is not only physically decapitating but also can lead to serious psychological
issues. Such complication is consequence of spinal cord ischaemia, which comes from
limited spinal cord blood flow during surgery, for which reports as high as 30% have
been described<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. To protect against such complication, various
adjunctive techniques have been developed to maintain appropriate spinal cord
circulation and reduce the incidence of spinal cord ischaemia, among such techniques
are: cerebrospinal fluid (CSF) drainage to reduce CSF pressure and increase spinal
cord perfusion<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, deep hypothermia which decreases the body&#x02019;s
metabolic activity and oxygen demand<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, sequential clamping and reattachment of
intercostal arteries<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>, and distal aortic perfusion<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>A leading technique these days to assess spinal cord function is measuring motor
evoked potentials (MEPs) intraoperatively, which potentially gives surgeons a
real-time assessment of spinal cord function<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. This method is used to alert surgeons to
identify impending spinal cord ischaemia and therefore have a chance to change their
intraoperative strategy to prevent postoperative paraplegia. However, in current
literature, there is much debate and uncertainties as to the usefulness and
application of MEPs and hence some centres do not routinely use it and yet, they
report low rates of paraplegia<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. There does not currently exist any high-level
evidence to show that the use of MEPs significantly decreases the incidence of
postoperative spinal cord ischaemia.</p><p>Current evidence from the literature suggest that there is release of specific
biomarkers into the CSF when there an ischaemic insult to brain or spinal
cord<sup>[<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r16" ref-type="bibr">16</xref>]</sup>. This has been extrapolated into thoracoabdominal
aneurysm repair because CSF drainage catheter is routinely applied in all
thoracoabdominal aneurysm elective repairs and there are certain research outputs
suggesting that there is an association of their appearance concurrently with spinal
cord ischaemia. Our current research is in the development of a novel microwave
sensor that can detect specific biomarkers in the CSF in real time, that we believe
could offer a better real-time assessment of the spinal cord intra and postoperative
thoracoabdominal aneurysm repair. In this review, we have systematically collated
all published information on the measured biomarkers in the CSF during
thoracoabdominal aneurysm repair and their relationship to SCI.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Search Strategy</title><p>Electronic searches were performed in PubMed, MEDLINE, EMBASE, Google Scholar,
SCOPUS, and Cochrane. No limits were placed on dates. Limits were placed on
articles published in the English language only. Search terms used included
thoracic aortic aneurysm OR thoracic aneurysm OR TAAR OR thoracic dissection OR
thoracic aorta OR thoracic aortic dissection AND intrathecal OR cerebrospinal
fluid OR CSF OR biomarker AND spinal cord ischaemia OR paraplegia OR paralysis
OR neurological deficit. To achieve maximum sensitivity, all search terms were
combined with Boolean operators and searched as both keywords and MeSH (Medical
Subject Headings) terms. Following exclusion of articles based on title or
abstract, full text articles selected had reference lists searched for any
potential further articles to be included in this review.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>In total, we found 15 papers that reported measurements of CSF biomarkers following
thoracoabdominal aneurysm repair. Those papers are summarized in <xref rid="t1" ref-type="table">Table 1</xref>. Biomarkers measured included
S-100&#x003b2;, NSE, lactate, LD, TNF-&#x003b1;, GFAp, Tau, glucose, HSP70, HSP27
interleukin 1&#x003b2;, IL-6, IL-8, IL-10, IL-12, and excitatory amino
acids<sup>[<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of studies included.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Year</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Total number of patients</th><th align="center" rowspan="1" colspan="1">Number of male patients (%)</th><th align="center" rowspan="1" colspan="1">Average age (range)</th><th align="center" rowspan="1" colspan="1">Number with neurological deficits</th><th align="center" rowspan="1" colspan="1">CSF biomarker studied</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">26 (55)</td><td align="center" rowspan="1" colspan="1">64 (35-89)</td><td align="center" rowspan="1" colspan="1">4 (5.8)</td><td align="center" rowspan="1" colspan="1">S-100B, NSE, LD</td></tr><tr><td align="left" rowspan="1" colspan="1">Casiraghi et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">10 (62.5)</td><td align="center" rowspan="1" colspan="1">63 (38-75)</td><td align="center" rowspan="1" colspan="1">4 (26.7)</td><td align="center" rowspan="1" colspan="1">Lactate</td></tr><tr><td align="left" rowspan="1" colspan="1">Drenger et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup></td><td align="center" rowspan="1" colspan="1">1997</td><td align="center" rowspan="1" colspan="1">Jerusalem, Baltimore and Nashville</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">65.3</td><td align="center" rowspan="1" colspan="1">3 (14.3)</td><td align="center" rowspan="1" colspan="1">Lactate</td></tr><tr><td align="left" rowspan="1" colspan="1">Brunnekreef et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3 (37.5)</td><td align="center" rowspan="1" colspan="1">68 (58-76)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">S-100B</td></tr><tr><td align="left" rowspan="1" colspan="1">Kunihara et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2001</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">9 (60)</td><td align="center" rowspan="1" colspan="1">60.6 (26-75)</td><td align="center" rowspan="1" colspan="1">1 (6.7%)</td><td align="center" rowspan="1" colspan="1">TNF-&#x003b1;, IL-1&#x003b2;, IL-6, IL-8, IL-10,
IL-12</td></tr><tr><td align="left" rowspan="1" colspan="1">van Dongen et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup></td><td align="center" rowspan="1" colspan="1">1998</td><td align="center" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7 (87.5)</td><td align="center" rowspan="1" colspan="1">63 (35-75)</td><td align="center" rowspan="1" colspan="1">1 (12.5)</td><td align="center" rowspan="1" colspan="1">S-100B</td></tr><tr><td align="left" rowspan="1" colspan="1">Kunihara et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2001</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">12 (52.2)</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">4 (17.4)</td><td align="center" rowspan="1" colspan="1">S100-B</td></tr><tr><td align="left" rowspan="1" colspan="1">Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2003</td><td align="center" rowspan="1" colspan="1">Sweden</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">2 (18.2)</td><td align="center" rowspan="1" colspan="1">S100-B, NSE, GFAp, lactate</td></tr><tr><td align="left" rowspan="1" colspan="1">Shiiya et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">64 (26-79)</td><td align="center" rowspan="1" colspan="1">6 (21.4)</td><td align="center" rowspan="1" colspan="1">S100-B, Tau</td></tr><tr><td align="left" rowspan="1" colspan="1">Khaladj et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2008</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">63 (27-71)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">S100-B, lactate, glucose</td></tr><tr><td align="left" rowspan="1" colspan="1">Hecker et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2008</td><td align="center" rowspan="1" colspan="1">Philadelphia</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">N/A (40-80)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">HSP70 and HSP27</td></tr><tr><td align="left" rowspan="1" colspan="1">Brock et al.<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup></td><td align="center" rowspan="1" colspan="1">1997</td><td align="center" rowspan="1" colspan="1">Baltimore</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">68.5</td><td align="center" rowspan="1" colspan="1">4 (25)</td><td align="center" rowspan="1" colspan="1">Glutamate, aspartate and glycine</td></tr></tbody></table></table-wrap><sec><title>S-100&#x003b2;</title><p>Seven studies reported levels of S-100&#x003b2; in the CSF as well as in patients
who suffered from SCI and compared to controls (summarized in <xref rid="t2" ref-type="table">Table 2</xref>)<sup>[<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup>. The results are
ambiguous as to whether high level of S-100&#x003b2; was associated with SCI or
can it be used as a marker to predict SCI intraoperatively as levels of
S-100&#x003b2; were not significantly higher in two studies for patients who
suffered from SCI compared to control group<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. In most studies,
the rise seen in S-100&#x003b2; as a late change in the CSF and hence not useful
as early predictive factor for SCI.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Studies that have analysed S-100&#x003b2; in CSF as comparative
analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">Number with neurological deficit (%)</th><th align="center" rowspan="1" colspan="1">Mean baseline S100b concentration</th><th align="center" rowspan="1" colspan="1">Peak S100b concentration in paraplegic group
(&#x000b5;g/l-1)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">4 (5.8)</td><td align="center" rowspan="1" colspan="1">5.625 &#x000b5;g/litre</td><td align="center" rowspan="1" colspan="1">10.375</td></tr><tr><td align="left" rowspan="1" colspan="1">Brunnekreef et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1.3 &#x000b5;g/litre</td><td align="center" rowspan="1" colspan="1">n/a</td></tr><tr><td align="left" rowspan="1" colspan="1">van Dongen et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1(12.5)</td><td align="center" rowspan="1" colspan="1">1.23 &#x000b5;g/litre</td><td align="center" rowspan="1" colspan="1">10.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Kunihara et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup></td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">4 (17.4)</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b5;g/litre</td><td align="center" rowspan="1" colspan="1">275</td></tr><tr><td align="left" rowspan="1" colspan="1">Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2 (18.2)</td><td align="center" rowspan="1" colspan="1">3.7 (1 [in log ng/l])</td><td align="center" rowspan="1" colspan="1">4.4 (in log ng/l)</td></tr><tr><td align="left" rowspan="1" colspan="1">Shiiya et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup></td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">6 (21.4)</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">42.35<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Khaladj et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">19.4[&#x000b1;14]</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Original values 72.2 [&#x000b1;40.8] and 12.5 [&#x000b1;5.5].</p></fn></table-wrap-foot></table-wrap><p>Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> described a prospective clinical study of 69
patients undergoing thoracoabdominal aneurysm repair were CSF samples taken at
times of induction of anaesthesia, application of aortic cross-clamping, 5 min,
then 2, 4, 6, 8 and 19 hours after reperfusion. These results were concomitantly
compared to serum samples and motor evoked potentials from transcranial
electrical stimulation and somatosensory evoked potentials (SSEP). In this
study, S-100&#x003b2; levels in the CSF could not be associated with silent
neurological damage or adverse neurological complications postoperatively.
However, CSF S-100&#x003b2; was higher in 75% of patients who suffered adverse
neurological complications postoperatively than the 90<sup>th</sup> percentile
of patients without neurological complications. The median concentration of CSF
S-100&#x003b2; remained virtually unchanged and within reference range without
adverse neurological complications.</p><p>Van Dongen et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> in their study described the measurements of
CSF S-100&#x003b2; in 8 patients undergoing open thoracoabdominal aneurysm
repair. CSF samples in those patients were collected at time of induction,
application of cross-clamping to aorta, 5 minutes following reperfusion, at skin
closure, and 24 hours postoperatively. Among those 8 patients operated on, one
suffered from delayed-onset postoperative paraplegia, and it was noted that CSF
S-100&#x003b2; continued to rise from skin closure and 24 hours postoperatively,
unlike the other 7 patients in whom S-100&#x003b2; decreased following skin
closure. In the patient with postoperative paraplegia, the MEP and SSEP
measurements intraoperatively did not show any significant abnormalities to
indicate presence of SCI.</p><p>Kunihara et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> prospectively studied 23 patients undergoing
TAAR or descending thoracic aortic aneurysm repair (DTAAR) who all had spinal
cord drainage and CSF measurement of S-100&#x003b2;, the samples were taken at
time of induction, 0, 6, 12, 18, 24, 48, and 72 hours postoperatively, among
those 23 patients, four of them suffered from SCI (paraplegia or paralysis). In
this study, S-100&#x003b2; levels were statistically increased 6 hours
postoperatively in those with SCI compared to those without evidence of SCI
(<italic>P</italic>&#x0003c;0.0010). These levels peaked at 48 hours (289
&#x000b1; 454 &#x000b5;g/L). In this study, there was a clear correlation between
S-100&#x003b2; CSF concentrations and SCI and the authors concluded that
S-100&#x003b2; seems to be a sensitive reliable biomarker to predict SCI.</p><p>Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> investigated 11 patients undergoing elective
DTAAR or TAAR and measured CSF S-100&#x003b2; level and furthermore measured the
concentrations of its isoforms (S-100A1B and S-100BB). Two out of eleven
patients suffered from postoperative neurological damage (1 stroke and 1
paraplegia). The patient who suffered from paraplegia developed this
complication 3 days postoperatively. In this patient, the S-100&#x003b2;
preoperative levels rose 20 hours after surgery and peaked (five folds higher
than preoperative value) on the 3<sup>rd</sup> postoperative day.</p><p>Khaladj et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> studied 13 patients undergoing TAAR and
measured their CSF S-100&#x003b2; level. CSF samples were taken for analysis at
time of induction, before and after application of aortic cross-clamping,
following this every 10 minutes intraoperatively and then every 30 minutes, once
on intensive care, samples were taken 3 times, then twice daily until removal of
the CSF drain. Among the 13 patients, two suffered from spinal cord, one of them
suffered severe cerebral ischaemia, as well as signs of SCI, peak CSF
S-100&#x003b2; was 400.8 &#x000b5;g/L on the first postoperative day, while CSF
S-100&#x003b2; levels continued to rise from the beginning of the operation in
those with SCI, but with highest levels seen at 6 hours.</p><p>Brunnekreef et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> studied 8 patients who underwent thoracic
endovascular stent grafting of the descending aorta. The patients were deemed at
high risk of suffering postoperative paraplegia as the aneurysm involved
critical intercostal arteries. CSF measurements were taken at induction, during
stenting, 6 hours following completion and 20 hours after repair. In this study,
no patient developed neurological deficit following graft stenting, their
baseline CSF S-100&#x003b2; concentrations were 0.9 to 1.7 &#x000b5;g/L.</p><p>Shiiya et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> describes 28 patients undergoing DTAAR or TAAR
and measurements of CSF S-100&#x003b2;. In this study, 3 patients developed SCI
and a further patient developed both SCI and brain infarction. In the latter,
CSF S-100&#x003b2; peaked at 965 &#x000b5;g/ml 48 hours postoperatively. A
subsequent patient with brain infarction without SCI showed a CSF S-100&#x003b2;
peak of 16.8 &#x000b5;g/ml. The other 3 patients who suffered SCI showed
statisically significant higher levels of CSF S-100&#x003b2; from 12 to 24 hours
postoperatively (median of 29.2 &#x000b5;g/ml and 72.2 &#x000b5;g/ml,
respectively). Interestingly, Shiiya et al. describes 3 patients who suffered
from temporary neurological deficit, their CSF S-100&#x003b2; rose following the
completion of surgery similar to the SCI group and above those without
neurological injury, however, levels of CSF S-100&#x003b2; decreased 24 hours
postoperatively to near baseline.</p><p>The current literature investigating the association of CSF S-100&#x003b2; to SCI
is limited. Furthermore, the results displayed are equivocal as to whether this
is a potential useful biomarker. The largest of the studies (Lases et
al.<sup>17</sup>) found that CSF S-100&#x003b2; did rise in 75% of those with
SCI, yet remained unchanged in the other 25% of the patients. However, in the
rest of studies, CSF S-100&#x003b2; rose in all patients who suffered from SCI,
interestingly the peak level of CSF S-100&#x003b2; was extremely variable between
studies<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>. For the most of the studies, increase in CSF
S-100&#x003b2; was a late marker of SCI and was noted following completion of the
operation, although a large majority of patients in these studies suffered from
late-onset postoperative SCI.</p></sec><sec><title>Lactate</title><p>Five studies have reported intraoperative lactate levels during thoracoabdominal
aneurysm repair<sup>17,21-25)]</sup>, however, only three studies compared
lactate CSF levels in patients with neurological deficit compared to controls
(<xref rid="t3" ref-type="table">Table 3</xref>)<sup>[<xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>. In these
patients, the lactate levels were significantly higher in patients that
developed SCI postoperatively. It is also imperative to mention that when
lactate was measured concomitantly with other biomarkers, it was the first
biomarker to raise<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>, nevertheless, such raise in lactate level was
non-specific as it was noted to raise at time of aortic cross-clamp application
in patients without developing SCI postoperatively.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Studies that have analysed lactate in CSF as comparative analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">Number with neurological deficit (%)</th><th align="center" rowspan="1" colspan="1">Mean baseline lactate concentration</th><th align="center" rowspan="1" colspan="1">Peak lactate concentration in paraplegic
group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">4 (5.8)</td><td align="center" rowspan="1" colspan="1">17.75 &#x000b5;g/l</td><td align="center" rowspan="1" colspan="1">25.625 &#x000b5;g/l</td></tr><tr><td align="left" rowspan="1" colspan="1">Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2 (18.2)</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b5;g/l</td><td align="center" rowspan="1" colspan="1">3 &#x000b5;g/l</td></tr><tr><td align="left" rowspan="1" colspan="1">Khaladj et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2.2 &#x000b5;g/l</td><td align="center" rowspan="1" colspan="1">9.3 &#x000b5;g/l</td></tr></tbody></table></table-wrap><p>Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, in the largest study of its kind, measured CSF
lactate in 69 patients undergoing DTAAR or TAAR. Among the 69 patients included
in the study, 4 developed adverse neurological complications. In this study,
lactate did not significantly rise in all 4 patients who developed neurological
complications and remained below the 90<sup>th</sup> percentile of patients
without adverse neurological outcomes.</p><p>Drenger et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> reported 21 patients who underwent TAAR and
described CSF lactate measurements intra and postoperatively. Among the group, 3
patients developed paraplegia, the mean CSF lactate in such patients were
significantly higher than those without evidence of SCI after removal of the
aortic cross-clamp, although this difference was not noted while the cross-clamp
is on.</p><p>Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> analysed CSF lactate level in 11 patients that
underwent DTAAR or TAAR, among those 11 patients, only one patient suffered from
postoperative paraplegia and the lactate CSF was high after bypass was
discontinued and the level remained elevated thereafter. However, this pattern
was also seen in some asymptomatic patients<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, as in a study by
Khaladji et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> who reported high CSF lactate level in 13
patients that underwent DTAAR or TAAR while only two 2 patients suffered
SCI.</p><p>Casiraghi et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> demonstrated that in 4 of 16 patients who
developed neurological injury following TAAR, CSF lactate was significantly
higher at all-time points including baseline, intra and postoperatively.</p></sec><sec><title>Neuron-Specific Enolase (NSE)</title><p>Neuron-specific enolase is a 78 kD gamma-homodimer and represents the dominant
enolase-isoenzyme found in neuronal and neuroendocrine tissues. Its levels in
other tissues, except erythrocytes, are negligible. The biological half-life of
NSE in body fluids is approximately 24 hours. A comparative NSE level in CSF was
measured in two studies (summarized in <xref rid="t4" ref-type="table">Table
4</xref>). Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> compared NSE to standard MEP monitoring in
their study. In their group of patients, 4 suffered postoperative paraplegia.
However, the association between CSF levels of NSE and postoperative paraplegia
was poorly correlated, among those patients that suffered SCI, 50% had levels of
NSE greater than the 90<sup>th</sup> percentile of patients with no adverse
neurological outcomes. The rise in CSF levels of NSE was at late stage in the
postoperative course (19 hours) and did not add value to the data obtained from
MEPs. The second study was conducted by Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. In this study,
the NSE level in patient with paraplegia was at the upper limit throughout the
procedure and this did not change significantly during the entire procedure,
however this was non-specific as the same increase was noted in patients who did
not develop any evidence of SCI, on the contrary, it was noted that one of the
patients who developed stroke postoperatively had a high level of serum NSE
which peaked at first postoperative day. Ultimately, their study shows poor
correlation between CSF and serum NSE value and, thus, prediction of SCI
(r=0.56, <italic>P</italic>=0.05).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Studies that have analysed NSE in CSF as comparative analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">Number with neurological deficit (%)</th><th align="center" rowspan="1" colspan="1">Mean baseline NSE concentration</th><th align="center" rowspan="1" colspan="1">Peak NSE concentration in paraplegic group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lases et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">4 (5.8)</td><td align="center" rowspan="1" colspan="1">12.625 &#x000b5;g/l</td><td align="center" rowspan="1" colspan="1">19 &#x000b5;g/l</td></tr><tr><td align="left" rowspan="1" colspan="1">Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2 (18.2)</td><td align="center" rowspan="1" colspan="1">12 &#x000b5;g/l</td><td align="center" rowspan="1" colspan="1">17 &#x000b5;g/l</td></tr></tbody></table></table-wrap></sec><sec><title>Tau</title><p>Tau is the major microtubule-associated protein (MAP) of a normal mature neuron,
it has two major functions, its ability to promote assembly and to maintain
structure of microtubules of the neurons, and therefore derangements in tau can
cause serious neurological issues.</p><p>In a study by Shiiya et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, they reported the levels of Tau protein in
CSF for 28 patients that underwent DTAAR or TAAR (summarized in <xref rid="t5" ref-type="table">Table 5</xref>). In their study, incidence of
postoperative spinal cord ischaemia was recorded in 4 of the 28 patients and TAU
was significantly associated with brain infarction, but it failed to rise at all
or detect spinal cord injury when compared to controls in this group of
patients. Therefore, use of such biomarker remains unpredictive for SCI during
open aortic repair surgeries.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Study that have analysed Tau level in CSF as comparative analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">Number with neurological deficit (%)</th><th align="center" rowspan="1" colspan="1">Mean baseline TAU concentration</th><th align="center" rowspan="1" colspan="1">Peak Tau concentration in paraplegic group</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Shiiya et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup></td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">6 (21.4)</td><td align="center" rowspan="1" colspan="1">134.25 pg/ml</td><td align="center" rowspan="1" colspan="1">989 pg/ml (massive confidence intervals)</td></tr></tbody></table></table-wrap></sec><sec><title>Heat Shock Proteins (HSP)</title><p>Heat shock proteins are a group of proteins that are produced in response to
stressful conditions; initially they were described in response to heat shock,
however later they were noted in other stressful tissue situations. A study by
Hecker et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> reported measurements of HSPs (HSP70 and HSP27)
in the CSF of 37 patients that underwent TAAR. CSF samples were taken at
baseline, at aortic cross-clamping, 1, 2, 12, 24 hours after cross-clamping, at
the completion of surgery, and if there were any signs of paraplegia. Fifteen
patients were reported as having postoperative paraplegia. In these patients the
cumulative averages and mean values of both HSP70 and HSP27 were larger than
patients who did not develop paraplegia. These values became statistically
significant at 12 and 24 hours postoperatively. Furthermore, they showed that
patients with non-linear HSP measurements overtime or had larger positive
average changes from pre- to post-cross-clamp time were more likely to
experience paraplegia.</p></sec><sec><title>Glial Fibrillary Acidic Protein (GFAp)</title><p>Glial fibrillary acidic protein is an intermediate filament protein that is
expressed by many cell types of the central nervous system. First described in
1971<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>, GFAp is thought to help in maintaining
astrocyte mechanical strength, however, it was first named, isolated and
characterized by Eng et al. in 1969<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><p>Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> reported the only study in which GFAp was
measured in 11 patients that underwent DTAAR or TAAR (summarized in <xref rid="t6" ref-type="table">Table 6</xref>). In this study, one patient
suffered delayed SCI and showed a 270-fold increase from baseline in CSF GFAp.
In this patient, paraplegia developed 30 hours after surgery; GFAp levels were
elevated before and after cardiopulmonary bypass, increasing 3-fold between 1
and 6 hours after surgery to 270-fold at 20 hours. On the contrary, one patient
showed raised postoperative GFAp levels despite no adverse neurological events
being noted.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Study that have analysed GFAp level in CSF as comparative analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">Number with neurological deficit (%)</th><th align="center" rowspan="1" colspan="1">Mean baseline GFAp concentration</th><th align="center" rowspan="1" colspan="1">Peak GFAp concentration in paraplegic group</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2 (18.2)</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">5</td></tr></tbody></table></table-wrap></sec><sec><title>Glucose</title><p>CSF glucose was measure during DTAAR or TAAR by Khaladj et
al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Two patients developed SCI and glucose
concentration was slightly increased in the SCI. However, this was not
statistically significant and did not correlate well to the occurrence of
SCI.</p></sec><sec><title>Inflammatory Cytokines</title><p>Kunihara et al.<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup> reported the CSF levels of proinflammatory
cytokines of 15 patients who underwent TAAR. Such proinflammatory cytokines
included TNF-&#x003b1;, IL-1&#x003b2;, IL-6, IL-8, IL-10 and IL-12, which were
measured at 0, 6, 12, 18, 24, 48 and 72 hours postoperatively. Among those 15
patients there was one patient that suffered paraplegia, while the remaining 14
non-paraplegic cases CSF IL-8 peaked postoperatively and continued to decline up
to 72 hours postoperatively. In contrast, the patient with paraplegia IL-8 CSF
rose postoperatively in consistent with the other 14 patients, however, IL-8
levels remained significantly high with no indication of decrease 72 hours
postoperatively. CSF IL-6 and TNF-&#x003b1; did not show any significant changes
throughout the study period. Interleukin-1&#x003b2; and IL-12 were undetectable
in all 15 patients and therefore could not be used as a guide for predicting
SCI.</p></sec><sec><title>Excitatory Amino Acids</title><p>The study by Brock et al.<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup> is the only one of its kind to report
levels of amino acids glutamate, aspartate and glycine in patients undergoing
DTAAR or TAAR. They studied a total of 16 patients, of whom 4 displayed lower
motor deficits postoperatively. They took measurements at baseline, at time of
application of aortic cross-clamp, early reperfusion (within 6 hours), mid
reperfusion (from 7 to 15 hours) and late reperfusion (over 15 hours).
Measurements from the SCI group showed significant differences in glutamate but
did not show differences in glycine level at all measurement&#x02019;s times, except
baseline. Aspartate showed significant increases in the SCI group during late
perfusion measurements only. Glutamate levels increased significantly across all
measurements; nearly threefold at time of aortic cross-clamp application (375%),
remained high at early reperfusion, but lowering to around 250%, before rising
at late reperfusion to approximately 400% of baseline.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Surgical intervention remains the recommended treatment in patients with
thoracoabdominal aortic aneurysms that cannot benefit from endovascular management,
this option is particularly important to prevent dissection or rupture and,
ultimately, death. Paraplegia remains a devastating complication of TAAR,
particularly when considering that many of such patients are being operated on at
elective basis. Several methods developed in light of the risk of paraplegia, such
as adjuncts to surgery like deep hypothermic circulatory arrest, circulatory
support, CSF drainage, and the use of different forms of intraoperative
neurophysiological monitoring (IONM) in the form of MEPs and
SSEP<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Those monitoring tools have a key role as an
adjunct-monitoring method while repairing the diseased aorta to predict the risk of
neurological injuries and provide rescue when it occurs and hence the outcomes could
be better when using such methods<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. In a large study by Estrera et al., of 105
complex aortic repairs CSF drainage, MEPs and SSEPs played a key role in early
detection of SCIs, such injuries were noted through alterations in the signals
conduction and therefore immediate actions were taken to revert
this<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>. Similar outcomes were also reported by Dong et al.
of the fact the both MEPs and SSEPs can predict spinal ischaemia and their
intraoperative use can prevent the development of paraplegia<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>. Finally, in a
systematic review and meta-analysis by Fok et al., they have reported the beneficial
use of IONM including both MEPs and SSEPs, however there is lack of general
consensus about the superiority or full recommendation of either
method<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>.</p><p>CSF biomarkers represent an area that has previously undergone much research within
the neurosurgical field, with particular respects to traumatic brain injury where
there are several ongoing clinical trials<sup>[<xref rid="r35" ref-type="bibr">35</xref>-<xref rid="r37" ref-type="bibr">37</xref>]</sup>. This research has begun to trickle into the
aortic world through small observational studies. Specific attention has focused on
the biomarkers lactate, S-100&#x003b2;, NSE and GFAp, which have all shown to be good
indicators correlating to injury magnitude in traumatic brain injury, as well as
outcomes and survival. The most promising potential biomarkers are S-100&#x003b2;,
GFAp and HSP, according to our analysis and published literature.</p><p>S-100&#x003b2; is part of the S100 protein family and the most widely studied
biomarker and is highly conserved in the mammalian brain, with the majority found in
large concentrations within the cytoplasm of astrocytes<sup>[<xref rid="r38" ref-type="bibr">38</xref>]</sup>. S-100&#x003b2; is a
neurotropic dimeric acidic Ca<sup>2+</sup> -binding protein with a molecular weight
of 21 kDa, existing in 2 &#x003b2; subunits (S-100&#x003b1;&#x003b2; heterodimer and
S-100&#x003b2;&#x003b2; homodimer). One study in this review differentiated between
the two subunits but found no relevance between the two, the majority of
commercially available assays do not differentiate between S-100&#x003b1;&#x003b2;
heterodimer and S-100&#x003b2;&#x003b2; homodimer<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r39" ref-type="bibr">39</xref>]</sup>.</p><p>The results for S-100&#x003b2; as a potential biomarker in TAAR to detect SCI have
been ambiguous. The largest of the studies involving 69 patients did not find
significant changes in CSF S-100&#x003b2; in those who suffered neurological
damage<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Despite this, other smaller studies have found
statistically significant associations of S-100&#x003b2; concentrations in CSF for
patients with neurological damage<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>. One study described concentrations of
S-100&#x003b2; and patients with temporary neurological damage and S-100&#x003b2;
would rise in a fashion similar to those who suffered permanent neurological damage,
but rather than plateau or continue to rise, would decrease back toward
baseline<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. This finding suggests that changes in
S-100&#x003b2; concentration may reflect temporary or permanent neurological damage.
However, the rise of S-100&#x003b2; was always a late sign of neurological damage,
whether this is a reflection of sample timing could be argued.</p><p>Although only investigated in one study<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, the data provided are suggestive
evidence that GFAp may serve as a biomarker for SCI in TAAR, or at least warrants
further investigation. GFAp is the principal 8-9 nm intermediate filament found in
mature fibrillary astrocytes. Astrogliosis is the morphological and functional
changes seen in astrocytes and occurs in response to a range of neurological
diseases or CNS injury, including ischaemia. This process has also been shown to
cause the increased expression of GFAp. Anderson et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> noted, combined with
the relative insolubilty of GFAp, increased concentrations could reflect structural
CNS damage and release into CSF would imply disintegration of cells containing
GFAp.</p><p>The highly conserved large family of heat shock proteins often coined as molecular
chaperones, found in all cells of all organisms, so called because of their initial
discovery when their dramatic up-regulation was detected following subjection of
cells to heat shock<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. They play crucial roles in folding/unfolding of
proteins, assembly of multiprotein complexes, transport/sorting of proteins into
correct subcellular compartments, cell-cycle control and signalling, and cell
protection against stress/apoptosis. Furthermore, following their discovery they are
released in a variety of other stresses, including ischaemia. Hecker et al. choose
to study HSP27 and HSP70 families for their association with cellular protection and
recovery after a near-lethal stress<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.</p><p>One of the main limiting factors in looking at the association between CSF biomarkers
and SCI is that detection of these markers requires extensive and immediate
laboratory testing. Consequently, this requires time, which is not ideal for
intraoperative use, specific equipment, which is expensive and furthermore needs
technical expertise. The ideal biomarker is one that is both sensitive and specific,
that can be rapidly, inexpensively and easily detected. Furthermore, there must be
good evidence to show that timely intervention in the presence of this biomarker
actually changes surgical outcomes. Although the quest for a biomarker continues, it
will require real-time detection to make intraoperative decisions to prevent SCI.
These requisites make the search for the biomarker to detect SCI in TAAR very
challenging.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>CSF may potentially hold clinically relevant information regarding SCI, however, this
is an under-researched area in the thoracic aortic surgery world. So far, to the
authors&#x02019; knowledge, the most promising candidates are heat shock proteins, GFAp and
S-100&#x003b2;. Detection of these biomarkers requires both time and financial
support as they have very dynamic changes in their concentrations and are hard to
measure experimentally. Our future research will be in the further development of a
real-time sensor that can detect small changes in the concentration of these
proteins.</p><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Author's roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AH</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CH</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LR</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MB</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Vascular Surgery, Countess of
Chester, Chester, UK.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashir</surname><given-names>M</given-names></name><name><surname>Fok</surname><given-names>M</given-names></name><name><surname>Hammoud</surname><given-names>I</given-names></name><name><surname>Rimmer</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><etal/></person-group><article-title>A perspective on natural history and survival in nonoperated
thoracic aortic aneurysm patients</article-title><source>Aorta</source><year>2013</year><volume>1</volume><issue>3</issue><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.12945/j.aorta.2013.13-043</pub-id><pub-id pub-id-type="pmid">26798691</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frederick</surname><given-names>JR</given-names></name><name><surname>Woo</surname><given-names>YJ</given-names></name></person-group><article-title>Thoracoabdominal aortic aneurysm</article-title><source>Ann Cardiothorac Surg</source><year>2012</year><volume>1</volume><issue>3</issue><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2225-319X.2012.09.01</pub-id><pub-id pub-id-type="pmid">23977509</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehrenbacher</surname><given-names>JW</given-names></name><name><surname>Corvera</surname><given-names>JS</given-names></name></person-group><article-title>Best surgical option for thoracoabdominal aneurysm repair - the
open approach</article-title><source>Ann Cardiothorac Surg</source><year>2012</year><volume>1</volume><issue>3</issue><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.3978/j.issn.2225-319X.2012.08.10</pub-id><pub-id pub-id-type="pmid">23977517</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>RK</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Roselli</surname><given-names>EE</given-names></name><name><surname>Svensson</surname><given-names>LG</given-names></name><name><surname>Moon</surname><given-names>MC</given-names></name><name><surname>Hernandez</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Contemporary analysis of descending thoracic and thoracoabdominal
aneurysm repair: a comparison of endovascular and open
techniques</article-title><source>Circulation</source><year>2008</year><volume>118</volume><issue>8</issue><fpage>808</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.769695</pub-id><pub-id pub-id-type="pmid">18678769</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cin&#x000e0;</surname><given-names>CS</given-names></name><name><surname>Abouzahr</surname><given-names>L</given-names></name><name><surname>Arena</surname><given-names>GO</given-names></name><name><surname>Lagan&#x000e0;</surname><given-names>A</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Farrokhyar</surname><given-names>F</given-names></name></person-group><article-title>Cerebrospinal fluid drainage to prevent paraplegia during
thoracic and thoracoabdominal aortic aneurysm surgery: a systematic review
and meta-analysis</article-title><source>J Vasc Surg</source><year>2004</year><volume>40</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2004.03.017</pub-id><pub-id pub-id-type="pmid">15218460</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>KH</given-names></name><name><surname>Ziganshin</surname><given-names>BA</given-names></name><name><surname>Elefteriades</surname><given-names>JA</given-names></name></person-group><article-title>Deep hypothermic circulatory arrest: real-life suspended
animation</article-title><source>Prog Cardiovasc Dis</source><year>2013</year><volume>56</volume><issue>1</issue><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2013.05.009</pub-id><pub-id pub-id-type="pmid">23993241</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safi</surname><given-names>HJ</given-names></name><name><surname>Miller 3rd</surname><given-names>CC</given-names></name><name><surname>Carr</surname><given-names>C</given-names></name><name><surname>Iliopoulos</surname><given-names>DC</given-names></name><name><surname>Dorsay</surname><given-names>DA</given-names></name><name><surname>Baldwin</surname><given-names>JC</given-names></name></person-group><article-title>Importance of intercostal artery reattachment during
thoracoabdominal aortic aneurysm repair</article-title><source>J Vasc Surg</source><year>1998</year><volume>27</volume><issue>1</issue><fpage>58</fpage><lpage>66</lpage><comment>discussion 66-8</comment><pub-id pub-id-type="pmid">9474083</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CC</given-names></name><name><surname>Kwan</surname><given-names>GN</given-names></name><name><surname>van Driel</surname><given-names>ML</given-names></name><name><surname>Rophael</surname><given-names>JA</given-names></name></person-group><article-title>Distal aortic perfusion during thoracoabdominal aneurysm repair
for prevention of paraplegia</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><issue>3</issue><elocation-id>CD008197</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD008197.pub2</pub-id><pub-id pub-id-type="pmid">22419329</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>RT</given-names></name><name><surname>Conrad</surname><given-names>MF</given-names></name><name><surname>Patel</surname><given-names>VI</given-names></name><name><surname>Cambria</surname><given-names>MR</given-names></name><name><surname>Ergul</surname><given-names>EA</given-names></name><name><surname>Cambria</surname><given-names>RP</given-names></name></person-group><article-title>Further experience with distal aortic perfusion and motor-evoked
potential monitoring in the management of extent I-III thoracoabdominal
aortic anuerysms</article-title><source>J Vasc Surg</source><year>2013</year><volume>58</volume><issue>2</issue><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2013.01.042</pub-id><pub-id pub-id-type="pmid">23796413</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrera</surname><given-names>AL</given-names></name><name><surname>Sheinbaum</surname><given-names>R</given-names></name><name><surname>Miller 3rd</surname><given-names>CC</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Safi</surname><given-names>HJ</given-names></name></person-group><article-title>Neuromonitor-guided repair of thoracoabdominal aortic
aneurysms</article-title><source>J Thorac Cardiovasc Surg</source><year>2010</year><volume>140</volume><issue>6 Suppl</issue><fpage>S131</fpage><lpage>S135</lpage><comment>discussion S142-S146</comment><pub-id pub-id-type="doi">10.1016/j.jtcvs.2010.07.058</pub-id><pub-id pub-id-type="pmid">21092779</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coselli</surname><given-names>JS</given-names></name><name><surname>Tsai</surname><given-names>PI</given-names></name></person-group><article-title>Motor evoked potentials in thoracoabdominal aortic surgery:
CON</article-title><source>Cardiol Clin</source><year>2010</year><volume>28</volume><issue>2</issue><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.ccl.2010.01.001</pub-id><pub-id pub-id-type="pmid">20452554</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Biomarkers of mild traumatic brain injury in cerebrospinal fluid
and blood</article-title><source>Nat Rev Neurol</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2013.9</pub-id><pub-id pub-id-type="pmid">23399646</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>BK</given-names></name><name><surname>Stammers</surname><given-names>AM</given-names></name><name><surname>Belanger</surname><given-names>LM</given-names></name><name><surname>Bernardo</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Bishop</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid inflammatory cytokines and biomarkers of
injury severity in acute human spinal cord injury</article-title><source>J Neurotrauma</source><year>2010</year><volume>27</volume><issue>4</issue><fpage>669</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1089/neu.2009.1080</pub-id><pub-id pub-id-type="pmid">20038240</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e5;rdemark</surname><given-names>HG</given-names></name><name><surname>Ericsson</surname><given-names>N</given-names></name><name><surname>Kotwica</surname><given-names>Z</given-names></name><name><surname>Rundstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Mendel-Hartvig</surname><given-names>I</given-names></name><name><surname>Olsson</surname><given-names>Y</given-names></name><etal/></person-group><article-title>S-100 protein and neuron-specific enolase in CSF after
experimental traumatic or focal ischemic brain damage</article-title><source>J Neurosurg</source><year>1989</year><volume>71</volume><issue>5</issue><issue-part>Pt 1</issue-part><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.3171/jns.1989.71.5.0727</pub-id><pub-id pub-id-type="pmid">2809727</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Wei</surname><given-names>CP</given-names></name><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Tseng</surname><given-names>YT</given-names></name><name><surname>Tsai</surname><given-names>MD</given-names></name><name><surname>Shih</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Inflammatory mediators of cerebrospinal fluid from patients with
spinal cord injury</article-title><source>Surg Neurol</source><year>2008</year><volume>70</volume><issue>Suppl 1</issue><fpage>S1</fpage><lpage>S1</lpage><pub-id pub-id-type="doi">10.1016/j.surneu.2007.09.033</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouw</surname><given-names>MH</given-names></name><name><surname>Kwon</surname><given-names>BK</given-names></name><name><surname>Verbeek</surname><given-names>MM</given-names></name><name><surname>Vos</surname><given-names>PE</given-names></name><name><surname>van Kampen</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Structural biomarkers in the cerebrospinal fluid within 24 h
after a traumatic spinal cord injury: a descriptive analysis of 16
subjects</article-title><source>Spinal Cord</source><year>2014</year><volume>52</volume><issue>6</issue><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/sc.2014.26</pub-id><pub-id pub-id-type="pmid">24710150</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lases</surname><given-names>EC</given-names></name><name><surname>Schepens</surname><given-names>MA</given-names></name><name><surname>Haas</surname><given-names>FJ</given-names></name><name><surname>Aarts</surname><given-names>LP</given-names></name><name><surname>ter Beek</surname><given-names>HT</given-names></name><name><surname>van Dongen</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Clinical prospective study of biochemical markers and evoked
potentials for identifying adverse neurological outcome after thoracic and
thoracoabdominal aortic aneurysm surgery</article-title><source>Br J Anaesth</source><year>2005</year><volume>95</volume><issue>5</issue><fpage>651</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1093/bja/aei239</pub-id><pub-id pub-id-type="pmid">16199420</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunnekreef</surname><given-names>GB</given-names></name><name><surname>Heijmen</surname><given-names>RH</given-names></name><name><surname>Gerritsen</surname><given-names>WB</given-names></name><name><surname>Schepens</surname><given-names>MA</given-names></name><name><surname>ter Beek</surname><given-names>HT</given-names></name><name><surname>van Dongen</surname><given-names>EP</given-names></name></person-group><article-title>Measurements of cerebrospinal fluid concentrations of S100beta
protein during and after thoracic endovascular stent
grafting</article-title><source>Eur J Vasc Endovasc Surg</source><year>2007</year><volume>34</volume><issue>2</issue><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2007.01.013</pub-id><pub-id pub-id-type="pmid">17408991</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dongen</surname><given-names>EP</given-names></name><name><surname>Ter Beek</surname><given-names>HT</given-names></name><name><surname>Boezeman</surname><given-names>EH</given-names></name><name><surname>Schepens</surname><given-names>MA</given-names></name><name><surname>Langemeijer</surname><given-names>HJ</given-names></name><name><surname>Aarts</surname><given-names>LP</given-names></name></person-group><article-title>Normal serum concentrations of S-100 protein and changes in
cerebrospinal fluid concentrations of S-100 protein during and after
thoracoabdominal aortic aneurysm surgery: is S-100 protein a biochemical
marker of clinical value in detecting spinal cord ischemia?</article-title><source>J Vasc Surg</source><year>1998</year><volume>27</volume><issue>2</issue><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/S0741-5214(98)70365-9</pub-id><pub-id pub-id-type="pmid">9510289</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunihara</surname><given-names>T</given-names></name><name><surname>Shiiya</surname><given-names>N</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name></person-group><article-title>Changes in S100beta protein levels in cerebrospinal fluid after
thoracoabdominal aortic operations</article-title><source>J Thorac Cardiovasc Surg</source><year>2001</year><volume>122</volume><issue>5</issue><fpage>1019</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1067/mtc.2001.115151</pub-id><pub-id pub-id-type="pmid">11689809</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RE</given-names></name><name><surname>Winnerkvist</surname><given-names>A</given-names></name><name><surname>Hansson</surname><given-names>LO</given-names></name><name><surname>Nilsson</surname><given-names>O</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Settergren</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biochemical markers of cerebrospinal ischemia after repair of
aneurysms of the descending and thoracoabdominal aorta</article-title><source>J Cardiothorac Vasc Anesth</source><year>2003</year><volume>17</volume><issue>5</issue><fpage>598</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/S1053-0770(03)00203-9</pub-id><pub-id pub-id-type="pmid">14579213</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiiya</surname><given-names>N</given-names></name><name><surname>Kunihara</surname><given-names>T</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name></person-group><article-title>Tau protein in the cerebrospinal fluid is a marker of brain
injury after aortic surgery</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>77</volume><issue>6</issue><fpage>2034</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2003.12.057</pub-id><pub-id pub-id-type="pmid">15172260</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaladj</surname><given-names>N</given-names></name><name><surname>Teebken</surname><given-names>OE</given-names></name><name><surname>Hagl</surname><given-names>C</given-names></name><name><surname>Wilhelmi</surname><given-names>MH</given-names></name><name><surname>Tschan</surname><given-names>C</given-names></name><name><surname>Weissenborn</surname><given-names>K</given-names></name><etal/></person-group><article-title>The role of cerebrospinal fluid S100 and lactate to predict
clinically evident spinal cord ischaemia in thoraco-abdominal aortic
surgery</article-title><source>Eur J Vasc Endovasc Surg</source><year>2008</year><volume>36</volume><issue>1</issue><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2008.01.011</pub-id><pub-id pub-id-type="pmid">18313337</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casiraghi</surname><given-names>G</given-names></name><name><surname>Poli</surname><given-names>D</given-names></name><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Buratti</surname><given-names>L</given-names></name><name><surname>Imberti</surname><given-names>R</given-names></name><name><surname>Plumari</surname><given-names>V</given-names></name><etal/></person-group><article-title>Intrathecal lactate concentration and spinal cord injury in
thoracoabdominal aortic surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>2011</year><volume>25</volume><issue>1</issue><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1053/j.jvca.2010.03.006</pub-id><pub-id pub-id-type="pmid">20570182</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drenger</surname><given-names>B</given-names></name><name><surname>Parker</surname><given-names>SD</given-names></name><name><surname>Frank</surname><given-names>SM</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name></person-group><article-title>Changes in cerebrospinal fluid pressure and lactate
concentrations during thoracoabdominal aortic aneurysm
surgery</article-title><source>Anesthesiology</source><year>1997</year><volume>86</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9009938</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>JG</given-names></name><name><surname>Sundram</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Praestgaard</surname><given-names>A</given-names></name><name><surname>Bavaria</surname><given-names>JE</given-names></name><name><surname>Ramchandren</surname><given-names>S</given-names></name><etal/></person-group><article-title>Heat shock proteins HSP70 and HSP27 in the cerebral spinal fluid
of patients undergoing thoracic aneurysm repair correlate with the
probability of postoperative paralysis</article-title><source>Cell Stress Chaperones</source><year>2008</year><volume>13</volume><issue>4</issue><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1007/s12192-008-0039-z</pub-id><pub-id pub-id-type="pmid">18418731</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunihara</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Shiiya</surname><given-names>N</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name><name><surname>Mafune</surname><given-names>N</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name></person-group><article-title>Proinflammatory cytokines in cerebrospinal fluid in repair of
thoracoabdominal aorta</article-title><source>Ann Thorac Surg</source><year>2001</year><volume>71</volume><issue>3</issue><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">11269455</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>MV</given-names></name><name><surname>Redmond</surname><given-names>JM</given-names></name><name><surname>Ishiwa</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>MV</given-names></name><name><surname>Baumgartner</surname><given-names>WA</given-names></name><name><surname>Laschinger</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Clinical markers in CSF for determining neurologic deficits after
thoracoabdominal aortic aneurysm repairs</article-title><source>Ann Thorac Surg</source><year>1997</year><volume>64</volume><issue>4</issue><fpage>999</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(97)00621-8</pub-id><pub-id pub-id-type="pmid">9354517</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name></person-group><article-title>Intermediate filaments: structure, dynamics, function, and
disease</article-title><source>Annu Rev Biochem</source><year>1994</year><volume>63</volume><fpage>345</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.63.070194.002021</pub-id><pub-id pub-id-type="pmid">7979242</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>LF</given-names></name><name><surname>Ghirnikar</surname><given-names>RS</given-names></name><name><surname>Lee</surname><given-names>YL</given-names></name></person-group><article-title>Glial fibrillary acidic protein: GFAP-thirty-one years
(1969-2000)</article-title><source>Neurochem Res</source><year>2000</year><volume>25</volume><issue>9-10</issue><fpage>1439</fpage><lpage>1451</lpage><pub-id pub-id-type="doi">10.1023/A:1007677003387</pub-id><pub-id pub-id-type="pmid">11059815</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marafona</surname><given-names>AS</given-names></name><name><surname>Machado</surname><given-names>HS</given-names></name></person-group><article-title>Intraoperative evoked potentials: a review of clinical impact and
limitations</article-title><source>J Anesth Clin Res</source><year>2018</year><volume>9</volume><issue>2</issue><fpage>805</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.4172/2155-6148.1000805</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrera</surname><given-names>AL</given-names></name><name><surname>Sheinbaum</surname><given-names>R</given-names></name><name><surname>Miller 3rd</surname><given-names>CC</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Safi</surname><given-names>HJ</given-names></name></person-group><article-title>Neuromonitor-guided repair of thoracoabdominal aortic
aneurysms</article-title><source>J Thorac Cardiovasc Surg</source><year>2010</year><volume>140</volume><issue>6 Suppl</issue><fpage>S131</fpage><lpage>S135</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2010.07.058</pub-id><pub-id pub-id-type="pmid">21092779</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>CC</given-names></name><name><surname>MacDonald</surname><given-names>DB</given-names></name><name><surname>Janusz</surname><given-names>MT</given-names></name></person-group><article-title>Intraoperative spinal cord monitoring during descending thoracic
and thoracoabdominal aneurysm surgery</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>5</issue><fpage>S1873</fpage><lpage>S1876</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(02)04137-1</pub-id><pub-id pub-id-type="pmid">12440684</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fok</surname><given-names>M</given-names></name><name><surname>Jafarzadeh</surname><given-names>F</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Abello</surname><given-names>D</given-names></name><name><surname>Rimmer</surname><given-names>L</given-names></name><name><surname>Howard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Is there any benefit of neuromonitoring during descending and
thoracoabdominal aortic aneurysm repair?</article-title><source>Innovations (Phila)</source><year>2015</year><volume>10</volume><issue>5</issue><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1097/IMI.0000000000000187</pub-id><pub-id pub-id-type="pmid">26536078</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harky</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Ahmad</surname><given-names>MU</given-names></name><name><surname>Howard</surname><given-names>C</given-names></name><name><surname>Rimmer</surname><given-names>L</given-names></name><name><surname>Bashir</surname><given-names>M</given-names></name></person-group><article-title>Thoracoabdominal aortic aneurysm surgery: a different perspective
on stent grafts failure</article-title><source>J Vis Surg</source><year>2019</year><volume>5</volume><fpage>3</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.21037/jovs.2019.01.01</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawthorne</surname><given-names>C</given-names></name><name><surname>Piper</surname><given-names>I</given-names></name></person-group><article-title>Monitoring of intracranial pressure in patients with traumatic
brain injury</article-title><source>Front Neurol</source><year>2014</year><volume>5</volume><fpage>121</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.3389/fneur.2014.00121</pub-id><pub-id pub-id-type="pmid">25076934</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mouhieddine</surname><given-names>TH</given-names></name><name><surname>El Houjeiri</surname><given-names>L</given-names></name><name><surname>Sabra</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>RL</given-names></name><name><surname>Mondello</surname><given-names>S</given-names></name></person-group><chapter-title>CNS trauma biomarkers and surrogate endpoints pipeline from bench
to bedside: a translational perspective</chapter-title><person-group person-group-type="author"><name><surname>Kobeissy</surname><given-names>FH</given-names></name></person-group><source>Brain Neurotrauma: Molecular,Neuropsychological, and Rehabilitation
Aspects</source><year>2015</year><publisher-loc>Boca Raton (FL)</publisher-loc><publisher-name>CRC Press, Taylor &#x00026; Francis</publisher-name><comment>Chapter 20</comment></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>The S100 protein family and its application in cardiac
diseases</article-title><source>World J Emerg Med</source><year>2010</year><volume>1</volume><issue>3</issue><fpage>165</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">25214961</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bak</surname><given-names>MJ</given-names></name><name><surname>Wewer Albrechtsen</surname><given-names>NJ</given-names></name><name><surname>Pedersen</surname><given-names>J</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Vilsb&#x000f8;ll</surname><given-names>T</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Specificity and sensitivity of commercially available assays for
glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in
clinical studies</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><issue>11</issue><fpage>1155</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1111/dom.12352</pub-id><pub-id pub-id-type="pmid">25041349</pub-id></element-citation></ref></ref-list></back></article>